Free tool
FAERS Monitor: Winlevi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213433 or its brand name (Winlevi, Clascoterone). Reports on generic versions are filed under their own applications.
Reports
1,419
Serious
75
5% of reports
Hospitalization
6
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product storage error333
- product physical consistency issue329
- product use complaint286
- product dose omission issue184
- product use issue153
- drug ineffective146
- therapy cessation86
- poor quality product administered84
- product physical issue78
- condition aggravated76
- product quality issue67
- acne46
- off label use38
- erythema30
- liquid product physical issue25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 500 |
| 2023 | 210 |
| 2024 | 422 |
| 2025 | 269 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product physical consistency issueSignal | 329 | 936.7 | 848.8 | 288,451 |
| product use complaintSignal | 286 | 274.0 | 246.8 | 76,182 |
| poor quality product administeredSignal | 84 | 119.1 | 96.7 | 9,645 |
| product physical issueSignal | 78 | 57.5 | 46.3 | 4,264 |
| product storage errorSignal | 333 | 56.6 | 51.5 | 18,137 |
| liquid product physical issueSignal | 25 | 51.0 | 34.5 | 1,172 |
| therapy cessationSignal | 86 | 24.9 | 20.3 | 1,948 |
| product use issueSignal | 153 | 12.1 | 10.4 | 1,556 |
| product dose omission issueSignal | 184 | 9.3 | 8.1 | 1,369 |
| acneSignal | 46 | 9.0 | 6.8 | 320 |
| product quality issueSignal | 67 | 7.3 | 5.8 | 361 |
| condition aggravatedSignal | 76 | 3.7 | 3.0 | 150 |
| erythemaSignal | 30 | 2.2 | 1.5 | 18 |
| drug ineffective | 146 | 1.6 | 1.4 | 38 |
| off label use | 38 | 0.6 | 0.5 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.